A detailed history of Oversea Chinese Banking Corp LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Oversea Chinese Banking Corp LTD holds 22,143 shares of BMY stock, worth $1.27 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
22,143
Previous 6,758 227.66%
Holding current value
$1.27 Million
Previous $280,000 308.93%
% of portfolio
0.03%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$39.66 - $51.75 $610,169 - $796,173
15,385 Added 227.66%
22,143 $1.15 Million
Q2 2024

Aug 05, 2024

BUY
$40.25 - $52.99 $272,009 - $358,106
6,758 New
6,758 $280,000
Q4 2023

May 21, 2024

BUY
$48.48 - $57.85 $210,548 - $251,242
4,343 New
4,343 $222,000
Q4 2023

Jan 31, 2024

SELL
$48.48 - $57.85 $46,977 - $56,056
-969 Reduced 18.24%
4,343 $222,000
Q3 2023

Apr 29, 2024

BUY
$57.89 - $64.73 $56,095 - $62,723
969 Added 22.31%
5,312 $308,000
Q3 2023

Nov 03, 2023

SELL
$57.89 - $64.73 $45,096 - $50,424
-779 Reduced 12.79%
5,312 $308,000
Q2 2023

Aug 08, 2023

SELL
$63.71 - $70.74 $120,348 - $133,627
-1,889 Reduced 23.67%
6,091 $389,000
Q1 2023

Sep 15, 2023

BUY
$65.71 - $74.53 $10,382 - $11,775
158 Added 2.02%
7,980 $553,000
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $10,382 - $11,775
158 Added 2.02%
7,980 $553,000
Q4 2022

Sep 15, 2023

BUY
$68.48 - $81.09 $118,538 - $140,366
1,731 Added 28.42%
7,822 $562,000
Q4 2022

Feb 13, 2023

BUY
$68.48 - $81.09 $535,650 - $634,285
7,822 New
7,822 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Oversea Chinese Banking Corp LTD Portfolio

Follow Oversea Chinese Banking Corp LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oversea Chinese Banking Corp LTD, based on Form 13F filings with the SEC.

News

Stay updated on Oversea Chinese Banking Corp LTD with notifications on news.